Sotera Health CoSHC +2.43%74 Days Payable is 53.06 as of Mar. 2026, which is 14% above its 10-year median of 46.54. GuruFocus rates SHC with a GF Score™ of 74/100 and a GF Value™ of $16.31 (Fairly Valued). The stock has 3 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Sotera Health Co ranks worse than 63.87% on this metric.
The historical rank and industry rank for Sotera Health Co's Days Payable or its related term are showing as below:
SHC'
s Days Payable Range Over the Past 10 Years
Min: 42.11 Med: 46.54 Max: 60.06
Current: 48
During the past 8 years, Sotera Health Co's highest Days Payable was 60.06. The lowest was 42.11. And the median was 46.54.
SHC's Days Payable is ranked worse than 63.87% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs SHC: 48.00
Sotera Health Co's Days Payable
increased
from Mar. 2025 (47.97) to Mar. 2026 (53.06).
It may suggest that Sotera Health Codelayed paying its suppliers.
Sotera Health Co Days Payable Related Terms
Sotera Health Co Days Payable Historical Data
* Premium members only.
The historical data trend for Sotera Health Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Sotera Health Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sotera Health Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotera Health Co (SHC) has a Days Payable of 53.06 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sotera Health Co and its competitors. This is 14% above median its historical median of 46.54. Over the past decade, Sotera Health Co's Days Payable has ranged from 42.11 to 60.06. According to the industry distribution chart, Sotera Health Co ranks #122 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 63.9%.
Is Sotera Health Co's Days Payable too high?
Sotera Health Co's current Days Payable of 53.06 is 14% above median its 10-year median of 46.54. Over the past 10 years, this metric has ranged from a low of 42.11 to a high of 60.06. The Medical Diagnostics & Research industry median Days Payable is 68.87. Sotera Health Co's value of 53.06 is 23% below this industry median. Based on the distribution chart, Sotera Health Co ranks #122 out of 191 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Sotera Health Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's Days Payable compare to BLLN and RDNT?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #122 out of 191 companies for Days Payable. This places Sotera Health Co in the lower half of its industry. The industry median Days Payable is 68.87. Sotera Health Co's value of 53.06 is 23% below this benchmark. Historically, Sotera Health Co's own Days Payable has ranged from 42.11 to 60.06 over the past decade. While the company's 10-year median is 46.54 vs. the industry median of 68.87, Sotera Health Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotera Health Co's current Days Payable of 53.06 is 23% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sotera Health Co and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotera Health Co's current Days Payable is 53.06, which is 14% above median its own 10-year median of 46.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Fairly Valued. The stock's GF Value™ is $16.31, compared to a current price of $17.10 — trading 4.8% above its estimated fair value. The current Days Payable is 53.06, which is 14% above median its 10-year median of 46.54 and 23% below the Medical Diagnostics & Research industry median of 68.87. Sotera Health Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sotera Health Co (SHC), the current Days Payable is 53.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $17.10 is trading 4.8% above its estimated GF Value™ of $16.31.
GuruFocus considers Sotera Health Co to be Fairly Valued.
Key valuation signals for SHC:
Days Payable: 53.06 (14% above median its 10-year median of 46.54)
GF Value™: $16.31 vs. price of $17.10 (4.8% above fair value)
Industry Position: 23% below the Medical Diagnostics & Research median (#122 of 191)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
74GF Score
Get the complete analysis for SHC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
